Jefferies: Multinational Pharma Companies Can Hardly Give Up China's Cost Efficiency
N.R. Finch
The Pentagon added WuXi AppTec to its "Chinese military company" list, but Jefferies analysts say the real-world impact is minimal — drug-pricing reform and patent cliffs make China's cost efficiency too valuable for multinationals to walk away from.
What does the blacklist actually do?
The Pentagon updated its Section 1260H list, expanding it from 134 to 188 entities. WuXi AppTec is the most prominent new addition in healthcare.
Being listed means a designation of ties to China's military, but it is not a trade ban — companies can still conduct normal business.
This means → The list's signal matters more than its legal bite. The real variable is whether harsher sanctions follow.
Why do analysts call the impact "minimal"?
Jefferies' head of Asia healthcare research, Cui Cui, says multinationals still prefer "made in China" for pharma — cost efficiency is the core driver.
The backdrop: global pharma faces drug-pricing reform and blockbuster patent expirations simultaneously, making cost reduction more urgent than ever.
In plain terms = Multinationals aren't staying in China out of loyalty. They've done the math — leaving is more expensive than staying.
What happened with the earlier Biosecure Act?
In late 2023, Congress introduced the Biosecure Act, naming WuXi AppTec, WuXi Biologics, BGI, MGI Tech, and Complete Genomics — five companies to be barred from federal contracts.
By the time the bill was signed into law last December, all five names had been removed.
This reflects the tug-of-war between political pressure and industrial reality — lawmakers ultimately recognized that forced decoupling costs too much.
How did the stock react?
WuXi AppTec's Hong Kong shares fell as much as 5.2% intraday on Tuesday, closing at HK$116.80 with the drop narrowing to 3.7%.
By Wednesday morning the stock rebounded 2.3% to HK$119.50, suggesting the market had largely digested the blacklist shock.
This means → The market completed a "panic → price → recover" cycle in under a day. Capital does not see fundamental damage.
Content is for reference only, not financial advice.